WaveLight AG / Quarter Results
18.06.2008
Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Press Release
WaveLight AG: Successful 9 months accounts with a growth in turnover of
over 31%
Significant improvement to EBIT in comparison with the previous year
Collaboration with the Alcon Group opens long-term turnover potential
Erlangen, 18th June, 2008. During the nine months of the current fiscal
year 2007/2008, WaveLight AG consequently and successfully continued its
dynamic growth path in the light of the strategic and operational
reorientation of the Group.
The Erlangen Company, WaveLight AG, listed in the Prime Standard of
Deutsche Börse AG increased its sales revenue from 31% to
65,190 thousand. The previous year's turnover was 49,528 thousand. At
the end of the 9 month reporting period as of 30th April, 2008, WaveLight
AG achieved earnings before interest and taxes (EBIT) totalling 6,198
thousand and also improved significantly on the previous year's result (
-577 thousand).
Market position successfully expanded in the U.S.A.
In the worldwide sales-strong US market, which is traditionally of great
importance for WaveLight for refractive surgery applications, the Company
generated in the nine months of the current fiscal year a stable result
with sales revenues of 28,550 thousand. It thus exceeded the turnover of
the comparable period in the previous year ( 17,185 thousand) by 66%.
In addition to the technologically leading product range of WaveLight, an
important basis for the positive development lies in the agreement
regarding the US market made between WaveLight AG and Alcon Laboratories,
Inc. in February, 2008.
Within the scope of this distribution agreement, Alcon Laboratories, Inc.
takes over distribution, sales and support functions as well as the
marketing of WaveLights refractive surgery product range for the US
market. In the wake of the agreement with WaveLight AG, Alcon Laboratories
Inc. has also guaranteed a fixed number of sales of laser systems within a
period of 3 years.
The collaboration of both companies was furthermore intensified and put on
a sound legal basis with the Domination Agreement between WaveLight AG and
the Alcon, Inc., already concluded in March 2008; which was approved by the
Extraordinary General Meeting of the Erlangen Company on the 7th May, 2008
in Munich and, in order to be effective still needs the registration in the
Commercial Register.
Positive turnover development in Asia
On 30th April, 2008, in the Asian sales region, the Erlangen Company
reached a turnover of 11,584 thousand and clearly excelled the previous
year's result ( 8,409 thousand) by more than 37%. Thus, in the third term
of the current fiscal year, WaveLight was able to build on the success of
the positive turnover development of the first six months on the Asian
markets, which are dynamically developing in the area of LASIK treatments.
Increase in turnover for the European market
Compared with the previous year, WaveLight was further able to expand its
market position in the European sales markets. The Company increased its
turnover as at 30th April, 2008 in comparison with the nine months of the
previous year ( 14,548 thousand) by over 13%, on a sales volume of
16,465 thousand.
Successful reorientation achieved
During the past nine months of the 2007/2008 fiscal year, WaveLight AG
successfully concluded the strategic and operational reorientation that
began in 2006/2007 fiscal year. In September, 2007, the separation from the
Aesthetics Division was effected with the sale of WaveLight Aesthetic GmbH.
In December, 2007, WaveLight's 100% stake in Berlin-based WaveLight GmbH
was sold to the Dutch company Medical Device Production B.V. (MDP B.V.) and
its 30% stake in MDP B.V. was sold to Procornea Holding B.V., based in
Eerbeek. At the same time, these transactions constituted the separation
from the applications of the intraocular surgery division.
Outlook: The sales and result targets for the 2007/2008 fiscal year
confirmed
Overall, the nine months of the current 2007/2008 fiscal year were
distinguished by a consistent, strategic and operational reorientation of
the WaveLight Group. In the future, WaveLight will be able to concentrate
exclusively on the development and production of technologically leading
treatment solutions for refractive surgery. The comprehensive agreement for
the US market made between WaveLight AG and Alcon Laboratories, Inc.
thereby opens up to the Erlangen Company additional, long-term potential
for turnover in the USA.
'On the basis of the already successful collaboration with the Alcon Group
and the continuous worldwide strong demand for WaveLight treatment systems,
we strongly expect successful accounts for the current fiscal year of
2007/2008,' declared Max Reindl, Chief Executive Officer of WaveLight AG.
'On the basis of the successful collaboration already set up with the Alcon
Group and, moreover, of the worldwide strong demand for WaveLight treatment
systems, we firmly assume that we shall successfully achieve our sales and
results targets at the end of the fiscal year,' declared Max Reindl, CEO of
WaveLight AG.
WaveLight AG (ISIN DE 000 512 5603)
The WaveLight AG Company, which has been listed in the Prime Standard of
Deutsche Börse AG since January 2003, develops, produces and sells a high
quality and complete product range in the field of ophthalmology and has
specialised in the intraocular lens. An innovative and technologically
leading product range and broadly established distribution using its own
channels and strategic partners are the basis of the market success of
WaveLight,
Further information about WaveLight can be found at www.wavelight.com
Contact person for the press:
Susanne Grethlein Gerhard Lodzwik
WaveLight AG AGIL Gesellschaft für Finanzkommunikation mbH
Tel.: + 49/9131/6186-103 Tel.: +49/2131/12 55 73
Fax: + 49/9131/6186-112 Fax: +49/2131/12 557 55
Email: susanne.grethlein@wavelight.com Email: info@AGIL-IR.com
Disclaimer:
Some of the statements made in this communication have the character of
prognoses or can be interpreted as such. All statements and assessments are
based on extremely conscientious research. However, no responsibility is
accepted for the accuracy of the information in this publication. Any
liability is ruled out. The statements above do not represent any
incitement for the purchase or sale of securities. All rights reserved.
DGAP 18.06.2008
---------------------------------------------------------------------------
Language: English
Issuer: WaveLight AG
Am Wolfsmantel 5
91058 Erlangen
Deutschland
Phone: +49 (0)9131 - 61 86-0
Fax: +49 (0)9131 - 61 86-111
E-mail: info@wavelight.com
Internet: www.wavelight.com
ISIN: DE0005125603
WKN: 512560
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Hannover, Düsseldorf, Hamburg, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: WaveLight AG: Successful 9 months accounts with a growth in turnover of over 31 %
| Source: EQS Group AG